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Abstract Photoaffinity labelling of hamster P-glycoprotein was 
carried out after trapping of radioactive Mg-8-azido-ADP in the 
catalytic sites by vanadate or beryllium fluoride. With either 
trapping agent the same labelled peptide was obtained in 
homogeneous form, with the sequence -FNEWFNxPTRPDI-, 
corresponding to residues 1034-1037 in the C-terminal nucleo-
tide binding site. The missing residue 'x' corresponds to Tyr-
1041, which is therefore a primary reaction target of 8-azido-
ADP. This tyrosine is conserved in all hamster, mouse and 
human P-glycoproteins. A second major labelled peptide fraction 
was also identified. The major sequence in this fraction was -
NIHFSxPSR-, corresponding to residues 393-401 of hamster P-
glycoprotein, where 'x' corresponds to Tyr-398 in the N-terminal 
nucleotide binding site. Therefore Tyr-398, which is also 
conserved in other P-glycoproteins, is also a reaction target for 
8-azido-ADP. In sequence alignment of the two nucleotide 
binding sites, Tyr-398 exactly corresponds to Tyr-1041. The data 
indicate that these two tyrosines lie close to the adenine ring of 
bound substrate MgATP in the respective catalytic sites of P-
glycoprotein. 
© 1997 Federation of European Biochemical Societies. 
Key words: Multidrug-resistance; P-glycoprotein; 
Catalytic site; Photoaffinity labelling 
1. Introduction 
P-glycoprotein (Pgp), also called multidrug-resistance pro-
tein, is a plasma membrane located glycoprotein. In vitro it 
has been shown to confer multidrug-resistance phenotype on 
cells. The mechanism is not yet understood in detail, but it is 
clear that Pgp has the capability of excluding drugs from cells 
in an ATP-dependent manner. The most commonly consid-
ered current hypothesis is that Pgp acts as an ATP-driven 
drug-export pump. Multidrug-resistance is an important ob-
stacle in treatment of human cancer, and there is considerable 
interest in the potential role of Pgp in rendering tumor cells 
resistant to chemotherapeutic drugs [1-5]. 
Pgp molecules from human and rodents show similar amino 
acid sequences, and are about 1280 residues in length, with 
two similar but not identical nucleotide binding sites (NBS). 
Pgp shows substantial ATPase activity in absence of added 
drugs ('basal activity'), which is stimulated several-fold by 
drugs [6]. The catalytic sites are known to be of low affinity 
for MgATP (AM ~ 1 mM) and of low selectivity for nucleo-
tides [7,8]. The photoaffinity labelling analog Mg-8-azido-ATP 
is a good hydrolysis substrate, with KM value of 0.50 mM 
[9,10]. 
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Photoaffinity labelling of catalytic sites in Pgp by nucleotide 
analogs is potentially valuable in a number of different ways. 
Determination of the target residue(s) reveals important in-
formation about the protein architecture. Such information 
also provides guidance in determining locations for specific 
insertion of Trp residues, which can serve as direct optical 
probes of catalytic site occupancy and binding properties, as 
recently demonstrated in Fi-ATPase [11]. Target residues for 
mutagenesis experiments aimed at elucidation of catalytic 
roles of critical residues may also be indicated. 
Earlier work has indicated that radioactive 8-azido-ATP 
covalently labels the NBS of Pgp upon UV-activation [9,12-
14]. However, because the affinity of Pgp for the analog is 
relatively low, the labelling stoichiometry achieved is also 
low unless very high concentrations of analog are used. Initial 
studies in our laboratory to identify target residue(s) in Pgp 
using radioactive analog alone were not successful. Later 
studies showed that substantial covalent labelling was 
achieved when either vanadate (Vi) or beryllium fluoride 
(BeFx) was used to trap 8-azido-ADP in the Pgp catalytic 
sites prior to UV-activation, that concentrations of only 10-
100 H-M nucleotide analog were adequate, and that highly 
specific labelling of Pgp in plasma membranes was achieved 
[15-18]. In this paper we took advantage of these trapping 
procedures to identify residues labelled by 8-azido-ADP in 
Pgp catalytic sites. 
2. Materials and methods 
2.1. Preparation of plasma membranes 
Plasma membranes were prepared from the multidrug-resistant Chi-
nese hamster ovary cell line CR1R12 [19] as described previously [15]. 
The membranes contained 15-20% (w/w) of Pgp as a fraction of total 
membrane protein, determined as in [9]. 
2.2. Trapping of 8-[a-32P]azido-ADP in catalytic sites of Pgp using 
vanadate or beryllium fluoride, followed by UV-photolysis 
Plasma membranes (6.7 mg of membrane protein) were incubated 
in 5 ml of 40 mM Tris-Cl pH 7.4, 0.1 mM EGTA, 2.1 mM MgS04, 50 
|xM verapamil, 100 u,M 8-azido-[oe-32P]ATP (53 dpm/pmol) for 20 min 
at 37°C in presence of either (a) 200 |xM sodium orthovanadate, or (b) 
1 mM NaF and 200 uM BeS04. Samples were then placed on ice in 
5 ml tissue culture dishes and subjected to UV-photolysis (X = 254 nm, 
1.1 mW/cm2, 5 min). It was confirmed by SDS-gel electrophoresis and 
autoradiography that under these conditions specific photolabelling of 
the Pgp band occurred, without discernible photocleavage of the Pgp. 
Calculated labelling stoichiometry in several experiments was 0.25-0.3 
mol 32P/mol Pgp, determined by counting of Pgp bands excised from 
SDS-gels. 
2.3. Trypsin fragmentation, Al-chelate resin affinity column 
chromatography, and HPLC fractionation of peptides 
Samples were first delipidated as follows. Methanol (16 ml), chloro-
form (8 ml) and water (10 ml) were added and samples were vigo-
rously vortexed at 23°C, then centrifuged at 3000 X g for 20 min at 
4°C. The top layer was discarded, methanol (18 ml) was added, and 
the sample was vortexed and centrifuged as above. The pellet was 
dried at room temperature overnight, then suspended in 330 (j.1 of 
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8 M urea (freshly deionised using AG501X8 resin, BioRad) plus 660 ul 
of 10 mM NH4HCO3, pH 8.0. The final pH was adjusted to 8.0 with 
1 M NH4OH. Trypsin was added at a ratio of 1/200 (trypsin/mem-
brane protein) and digestion was allowed to proceed for 24 h at 37°C, 
during which time all particulate material dissolved. 
Al-chelate resin affinity chromatography was carried out as de-
scribed [20,21]. Labelled peptides were eluted with 50 mM ammonium 
acetate pH 8.0, 15 mM KH2PO4, counted by Cerenkov counting, 
pooled and concentrated at room temperature to 2 ml final volume 
(SpeedVac SCI 10, Savant). 
The concentrate was applied directly to an HPLC column (Aqua-
pore RP300 7 micron C8, 250x4.6 mm, Brownlee Labs). Elution of 
peptides was carried out at a flow rate of 0.5 ml/min, with 100% 
Buffer A (0-10 min) and then with a gradient of 0-100% Buffer B 
(10-70 min). (Buffer A: 0.1% trifluoroacetic acid in water; Buffer B: 
0.09% trifluoroacetic acid in 70% acetonitrile/30% water.) Radioactiv-
ity in the fractions was monitored as above (see e.g. Fig. 2). Peak 
fractions were concentrated at room temperature (SpeedVac). 
2.4. Peptide sequencing 
Labelled peptides were sequenced at the University of Kentucky 
Peptide Sequencing Facility (Dr. Carol Beach, Director) using an 
Applied Biosystems Model 477A Protein Sequenator. 
2.5. Materials 
8-azido-[a-32P]ATP was from Research Products International. 
Trypsin was from Promega (Sequencing grade modified trypsin, 
Cat. No. V5111). Tissue culture materials were from BRL Life Tech-
nology Inc. 
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Fig. 2. HPLC analysis of the labelled peptide fraction obtained 
from elution of the Al-chelate resin affinity column. The radioactive 
peptide fraction obtained from the Al-chelate resin affinity chroma-
tography (Fig. 1) were applied to a C8 HPLC column and eluted as 
described in Section 2. Radioactivity in the eluates was monitored 
by Cerenkov counting of the 32P. Fractions at 51 and 64 min were 
taken for sequencing. Similar elution profiles were seen whether Vi 
or BeFx was the trapping agent. 
3. Results 
Previously we developed a multidrug-resistant Chinese 
hamster ovary cell line (CR1R12) which overexpresses Pgp. 
Plasma membranes isolated from these cells contain 15-20% 
by weight of Pgp, in the normal mammalian lipid environ-
ment [19]. We demonstrated that on incubation of Mg-8-azi-
do-[oc-32P]ATP and either Vi or BeFx with CR1R12 plasma 
membranes, Pgp ATPase activity is inhibited by trapping of 
stoichiometric amount (1 mol/mol) of Mg-8-azido-[ce-32P]ADP 
in catalytic sites [15,17]. Subsequent UV-illumination induces 
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Fig. 1. Al-chelate resin affinity chromatography of labelled tryptic 
peptides. Pgp in plasma membranes was incubated with Mg-8-azi-
do-[a-32P]-ATP and Vi, the trapped radioactive 8-azido-ADP was 
photoactivated with UV-light, and the labelled membranes were di-
gested with trypsin. The trypsin digest was applied to an Al-chelate 
resin affinity column. The nucleotide labelled peptides are preferen-
tially adsorbed to this column, and elution with 15 mM KH2PO4-
containing buffer released them (fractions 46-48). For further details 
see Section 2. When BeFx was used in place of Vi, the same results 
were seen. 
labelling of the Pgp by the trapped radioactive nucleotide. We 
followed these procedures here to obtained labelled Pgp. 
Labelled protein was delipidated, subjected to trypsin diges-
tion, and applied to an Al-chelate resin affinity column 
[20,21]. In the latter procedure the nucleotide analog labelled 
peptides are preferentially adsorbed to the column, and are 
then eluted specifically by phosphate buffer. A typical experi-
ment is shown in Fig. 1. The radioactive fractions eluted by 
the phosphate buffer were pooled, concentrated and applied 
to a C8 HPLC column. A typical profile for elution of radio-
activity from this column is shown in Fig. 2. A large, initial 
'flow-through' peak was seen, followed by two distinct major 
radioactive fractions, eluting at 51 min and 64 min, respec-
tively. Spectrophotometric monitoring of the HPLC column 
at 214 nm revealed distinct peaks at 51 and 64 min, but with a 
large background (data not shown). This is not unexpected 
since whole plasma membranes were used here as Pgp source 
material. For both Vi- or BeFx-trapped samples, the same 
elution profiles were seen on both Al-chelate resin affinity 
and HPLC columns. 
Sequencing of the 64 min peak revealed a single amino acid 
sequence over the first 14 cycles with no other residues de-
tected in significant amount. The results are shown in Table 1. 
The same sequence was obtained from both Vi- and BeFx-
trapped samples, once with Vi and two times with BeFx. The 
sequence obtained is -FNEWFNxPTRPDI- , corresponding 
to residues 1034 to 1047 of hamster isoform Pgpl [22], which 
is known to be the Pgp isoform present in CR1R12 plasma 
membranes [9], residue 1033 of Pgpl is Lys, consistent with 
trypsin cleavage, and the missing residue 'x' in the sequence 
corresponds to Tyr-1041. It is well established that 8-azido-
ADP commonly labels Tyr in nucleotide binding sites, and the 
data show that Tyr-1041 is a primary target residue for 8-
azido-ADP in the C-terminal NBS of Pgp. 
Sequencing of the 51 min peak in each of three differ-
ent experiments (comprising Vi- and BeFx-trapped sam-
ples) showed that in no case it was homogeneous. How-
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Table 1 
Sequence of the radioactive peak eluting at 64 min from the HPLC 
column 
Cycle Vi-trapped 8-azido-ADP BeFx-trapped 8-azido-ADP 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
(aa) 
Phe 
Asn 
Glu 
Val 
Val 
Phe 
Asn 
Xaa 
Pro 
Thr 
Arg 
Pro 
Asp 
He 
(pmol)a 
302.6 
212.9 
176.3 
213.6 
221.5 
231.0 
117.8 
64.2 
29.9 
19.1 
26.9 
36.7 
103.7 
(aa) 
Phe 
Asn 
Glu 
Val 
Val 
Phe 
Asn 
Xaa 
Pro 
Thr 
Arg 
Pro 
Asp 
lie 
(pmol)a 
102.8 
138.8 
132.3 
125.1 
87.3 
84.3 
83.8 
28.0 
15.5 
23.2 
22.3 
65.0 
85.5 
aYield of phenylthiohydantoin amino acid (aa) derivatives. In cycle 8 
(X) no amino acid derivative was detected in significant amount, an 
unusual peak eluted just before the histidine derivative. 
ever the major peptide sequence detected in all cases was 
-NIHFSxPSR-, corresponding to residues 393^101 of ham-
ster isoform Pgpl. Residue 392 is Lys, consistent with trypsin 
cleavage, and the missing residue 'x' corresponds to Tyr-398. 
When the sequences of the N- and C-terminal nucleotide sites 
of hamster Pgpl are aligned [22] it is seen that residue Tyr-398 
exactly corresponds to residue Tyr-1041. Since it is established 
that after Vi- or BeFx-trapping of 8-azido-ADP, followed by 
UV-illumination, both NBS of Pgp become labelled [16,17], 
we feel confident in stating that residue Tyr-398 is also a 
target residue for labelling of Pgp by 8-azido-ADP. 
The data indicated that other sites of labelling by 8-azido-
ADP occurred, and this is not unreasonable considering that 
the NBS of Pgp are known to be conformationally flexible [7]. 
Further fractionation of the 'flow-through' peak seen in Fig. 2 
on a C18 HPLC column revealed several radioactive peaks, 
but in low yield. Moreover, sequencing revealed that they 
were still heterogeneous. Larger amounts of material than 
are currently available will be required to follow up this as-
pect. 
Several labelling experiments were performed with purified 
Pgp, but were not successful. Our preparation of purified Pgp 
[10] contains a high lipid/protein ratio, and we ascribe our 
experimental difficulties to this fact. Future work will be 
aimed at obtaining active, pure Pgp preparations at low lip-
id/protein ratio. 
4. Discussion 
We demonstrate that 8-azido-ADP covalently labels residue 
Tyr-1041 of hamster Pgp isoform 1, contained within the se-
quence -FNEVVFNYPTRPDI- corresponding to residues 
1034-1047. The same Tyr is present, within very similar ad-
jacent sequences, in hamster Pgp2 and Pgp3, in human mdrl 
and mdr2, and in all three Pgp isoforms in the mouse. It lies 
32 residues upstream of the Lys of the Walker A consensus 
sequence, in the second (C-terminal) NBS of Pgp. Our results 
show that Tyr-1041 is a primary target residue of 8-azido-
ADP and indicate that it lies close to the adenine ring of 
bound substrate MgATP. 
In the past, the C-terminal NBS of Pgp has usually been 
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predicted to start at a later point in the sequence than residue 
1041. It may be recalled, however, that predictions of the 
starting position of the catalytic nucleotide binding domain 
in Fi-ATPase ß-subunit [23] required revision after the X-ray 
structure [24] revealed that the nucleotide binding domain 
actually started well upstream from the predicted position. 
Both Pgp nucleotide binding sites contain Walker A and B 
consensus sequences, which were originally discovered from 
studies of Fi-ATPase [25]. Thus Fi-ATPase may provide a 
useful analogy for Pgp. In Fi-ATPase catalytic sites a Tyr 
residue (ßTyr-331) is stacked against, and makes Van der 
Waals contact with, the adenine ring of bound nucleotide 
[11], thereby playing an important role in binding and orient-
ing the substrate. A similar role might exist for Tyr-1041 in 
Pgp. Substitution of Fi-ATPase ßTyr-331 by Trp provided a 
valuable direct optical probe of nucleotide binding [11] and it 
will be interesting to determine whether the mutation Y1041W 
in Pgp can provide a similar, specific optical probe in the C-
terminal nucleotide site of Pgp. It may also be mentioned that 
in Fx-ATPase, aromatic and hydrophobic residues surround 
the base moiety of bound substrate [24], and that the Pgp 
peptide sequence found above contains several such residues. 
Our data indicated that residue Tyr-398 of Pgp is also la-
belled by 8-azido-ADP because the sequence -NIHFSxPSR-
corresponding to Pgp residues 393^101 (where 'x'= Tyr-398), 
was the major sequence present in three different experiments 
in the labelled fraction eluting at 51 min in Fig. 2. When the 
sequences of the two Pgp nucleotide binding sites are aligned 
it is seen that Tyr-398 in the N-terminal NBS is equivalent to 
Tyr-1041 in the C-terminal NBS and like the latter, it lies 32 
residues upstream of the Walker A consensus sequence Lys 
residue. The discussion presented above regarding residue 
Tyr-1041 therefore applies equally to residue Tyr-398. 
In conclusion, this work has identified two Tyr residues, 
one in each NBS of Pgp, which lie close to the adenine ring 
of bound substrate MgATP and are very good candidates for 
Trp substitution and mutagenic analysis. 
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